DAVID BRYANT6 Jun 2025 17:10
Apologies if already posted. David Bryant's only role in life right now (apart from new position with Avacta) is as an advisor to Healthcare Royalty.
'Mr. Bryant, who is based in the UK, will assist HCRx in identifying potential royalty acquisition and credit opportunities across the United Kingdom ..'
'HCRx closed a new vehicle that will focus primarily on providing debt solutions to emerging biopharmaceutical companies. '
'HCRx believes emerging biopharmaceutical companies are increasingly interested in utilizing debt financing to help fund new product launches and product development. '
Now why would Bryant take up a Non-Exec position with Avacta if they weren't a strong contender for a bit of dosh from HCRx? and why was the position announced just before the Results and not at the AGM?
'Jan 3, 2024
STAMFORD, Conn.--(BUSINESS WIRE)--HealthCare Royalty (“HCRx” or the “Company”), a leading middle market royalty acquisition firm that has invested $5+ billion in over 85 biopharmaceutical products since inception, today announced several important firm developments:
Closing of Additional Vehicle Focused on Debt Investments
HCRx closed a new vehicle that will focus primarily on providing debt solutions to emerging biopharmaceutical companies. Between this new fund and the firm’s inaugural debt-focused vehicle, closed in October, HCRx now has over $250 million available for debt transactions. HCRx believes emerging biopharmaceutical companies are increasingly interested in utilizing debt financing to help fund new product launches and product development. With two new vehicles and its permanent capital entity, HCRx looks forward to continuing its leadership in providing innovative capital to the biopharma industry in 2024.
Appointment of David Bryant as HCRx Adviser for the United Kingdom and European Union
HCRx is pleased to announce that David Bryant has agreed to become an adviser to the firm for the UK and Europe.
Mr. Bryant, who is based in the UK, will assist HCRx in identifying potential royalty acquisition and credit opportunities across the United Kingdom and European Union. David brings a wealth of pharmaceutical, transactional, and operational experience having served as the Chief Business Officer at Clinigen for over ten years through its acquisition by Triton Partners. Prior to Clinigen, David served for two decades in commercial roles at Pfizer and GlaxoSmithKline. “We are fortunate to have someone with David’s experience as a resource in the UK and Europe,” stated Clarke B. Futch, Founder, Chief Executive Officer and Chairman at HCRx; “We look forward to growing our presence in the European biopharma ecosystem.”
Sign In
Follow the stocks
